Breast Cancer

, Volume 7, Issue 3, pp 187–190 | Cite as

Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report

  • Takao Yokoe
  • Yuichi lino
  • Yasuo Morishita
Original Article

Abstract

Background

We reported that IL-6 and IL-8 levels at the beginning of treatment are predictive indicators of response to therapy and prognosis of patients with recurrent breast cancer. The aim of this study was to investigate the trend of IL-6 and IL-8 levels in heavily pretreated patients with recurrent breast cancer.

Methods

Cytokine level trends in 12 patients heavily pretreated with anthracyclines were studied. Patients were divided into two groups according to the objective response. There were 5 partial response (PR)/no change (NC), and 7 progressive disease (PD) patients. Blood was taken every four weeks. IL-6 was measured by chemiluminescent enzyme immunoassay. IL-8 was measured by ELISA.

Results

The pretreatment level of IL-6 in the PR/NC group (11.0±2.1 pg/ml) was significantly lower than that (15.3±2.7 pg/ml) in the PD group. However, there was no difference in IL-8 level between the PR/NC group (12.5±5.5 pg/ml) and the PD group (11.5±1.1 pg/ml). IL-6 levels in the PR/NC group were maintained within normal levels or decreased to within normal levels after treatment, while levels of IL-6 in the PD group gradually increased until the time of patient death. A decrease in IL-8 level after treatment was observed in only one patient in the PR/NC group. Mild increase of IL-8 levels was observed in the PD group.

Conclusion

Continuous elevation of IL-6 levels indicates poor prognosis in heavily pretreated patients with recurrent breast cancer. Combination therapy including agents that reduce IL-6 levels will be a new strategy for aggressively treating recurrent breast cancer.

Key words

Cytokine IL-6 IL-8 Recurrent breast cancer 

Abbreviation

IL

Interleukin

TNF

Tumor necrosis factor

PR

Partial response

NC

No change

PD

Progressive disease

ELISA

Enzyme-linked immunosorbent assay

SEM

Standard error of the mean

MPA

Medroxyprogesterone acetate

5′DFUR

Doxifluridine

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    Kushner I: The acute phase response: An overview.Methods Enzymol 163:373–383, 1988.PubMedCrossRefGoogle Scholar
  2. 2).
    Hirano T, Yasukawa K, Harada H,et al: Complementary DNA for a novel human interleukin (BSF-s) that induces B lymphocytes to produce immunoglobulin.Nature 324:73–76, 1986.PubMedCrossRefGoogle Scholar
  3. 3).
    Kishimoto T: The biology of interleukin-6.Blood 74:1–10, 1989.PubMedGoogle Scholar
  4. 4).
    Detmers PA, Lo SK, Olsen-Egbert E,et al: Neutrophil-activated protein 1/interleukin-8 stimulates the binding activity of the leukocyte adhesion receptor CDllb/CD18 on human neutrophils.J Exp Med 171:1155–1162, 1990.PubMedCrossRefGoogle Scholar
  5. 5).
    Huber AR, Kunkel SL, Todd RF,et al: Regulation of transendothelial neutrophil migration by endogenous interleukin-8.Science 254:99–102, 1991.PubMedCrossRefGoogle Scholar
  6. 6).
    Strassman G, Fong M, Kenney JS,et al: Evidence for the involvement of interleukin 6 in experimental cancer cachexia.J Clin Invest 89:1681–1684, 1992.CrossRefGoogle Scholar
  7. 7).
    Yasumoto K, Mukaida N, Harada A,et al: Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice.Cancer Res 55:921–927, 1995.PubMedGoogle Scholar
  8. 8).
    Kajimura N, Iseki H, Tanaka R,et al: Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines.Cancer Chemother Pharmacol 38:48–52, 1996.CrossRefGoogle Scholar
  9. 9).
    Bobus VJ, Moll R, Gerharz DG,et al: Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin.Int J Cancer 77:415–423, 1998.CrossRefGoogle Scholar
  10. 10).
    Kurebayashi J, Otsuki T, Tang CK,et al: Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.Br J Cancer 79:707–717, 1999.PubMedCrossRefGoogle Scholar
  11. 11).
    Yokoe T, Lino Y, Takei H,et al: Changes of cytokines and thyroid function in patients with recurrent breast cancer.Anticancer Res 17:695–700, 1997.PubMedGoogle Scholar
  12. 12).
    Zhan GJ, Adachi I: Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast cancer.Anticancer Res 19 (2B): 1427–1432, 1999.Google Scholar
  13. 13).
    Reiter Z, Chen L, Revel M,et al: Interleukin-6 protects ductal breast carcinoma cells from MHC-unrestricted cell-mediated cytotoxicity.Lymphokine Cytokine Res 11:175–181, 1992.PubMedGoogle Scholar
  14. 14).
    Reed MJ, Topping L, Goldham NG,et al: Control of aromatase activity in breast cancer cells: The roll of cytokines and growth factors.J Steroid Biochem Molec Biol 44:589–596, 1993.PubMedCrossRefGoogle Scholar
  15. 15).
    Purohit A, Ghilchik MW, Duncan L,et al: Aromatase activity and interleukin-6 production by normal and malignant tissues.J Clin Endocrinol Metab 80:3052–3058, 1995.PubMedCrossRefGoogle Scholar
  16. 16).
    Asgeirsson KS, Olafsdottir K, Jonasson JG,et al: The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer.Cytokine 10:720–728, 1998.PubMedCrossRefGoogle Scholar
  17. 17).
    Kishimoto T, Akira S, Taga T: IL-6 receptor and mechanism of signal transduction.Int J Immunopharmacol 14:431–438, 1992.PubMedCrossRefGoogle Scholar
  18. 18).
    Kishimoto T: Interleukin-6 and its receptor in autoimmunity.J Autoimmun 5 Suppl A:123–132, 1992.PubMedCrossRefGoogle Scholar
  19. 19).
    Haverty AA, Harmey JH, Redmond HP,et al: Interleukin-6 upregulates GP96 expression in breast cancer.J Surg Res 69:145–149, 1997.PubMedCrossRefGoogle Scholar
  20. 20).
    Yokoe T, Lino Y, Takei H,et al: Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer.Anticancer Res 16:2069–2072, 1996.PubMedGoogle Scholar
  21. 21).
    Pittman CS, Suda AK, Chambers JB,et al: Abnormalities of thyroid hormone turnover in patients with diabetes mellitus before and after insulin therapy.J Clin Endocrinol Metab 48:854–860, 1979.PubMedGoogle Scholar
  22. 22).
    Wiersinga WM, Lie KI, Touber JL: Thyroid hormones in acute myocardial infarction.Clin Endoclinol 14:367–374, 1981.CrossRefGoogle Scholar
  23. 23).
    Lim VS, Fang VS, Kats AI,et al: Thyroid dysfunction in chronic renal failure.J Clin Invest 60:522–534, 1977.PubMedCrossRefGoogle Scholar
  24. 24).
    Nomura S, Pittman CS, Chambers JB,et al: Reduced peripheral conversion of thyroxin to triiodothyronine in patients with hepatic cirrhosis.J Clin Invest 56:643–652, 1975.PubMedCrossRefGoogle Scholar
  25. 25).
    Davidson SB, Dulchafsky SA, Diebel LN,et al: Effect of sepsis and 3,5,3’-triiodothyronine replacement on myocardial integrity during oxidant challenge.Crit Care Med 24:850–854, 1996.PubMedCrossRefGoogle Scholar
  26. 26).
    Walker JD, Crawford FA, Mukherjee R,et al: Direct effect of acute administration of 3,5,3’-triiodo-L-thyronine on myocyte function.Ann Thorac Surg 58:851–856, 1994.PubMedCrossRefGoogle Scholar
  27. 27).
    Morkin E, Pennock GD, Raya TE,et al: Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure.Ann Thorac Surg 56:S54–60, 1993.Google Scholar
  28. 28).
    Dulchafsky SA, Kenzenko SM, Saba AA,et al: Triiodothyronine (T3) supplementation maintains surfactant biochemical integrity during sepsis.J Trauma 39:53–58, 1995.CrossRefGoogle Scholar
  29. 29).
    Yamashita J, Hideshima T, Shirakusa T,et al: Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma.Cancer 78:2346–2352, 1996.PubMedCrossRefGoogle Scholar
  30. 30).
    Kurebayashi J, Yamamoto S, Otsuki T,et al: Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells bothin vitro andin vivo; A possible mechanism of the anticachectic effect.Br J Cancer 79:631–636, 1999.PubMedCrossRefGoogle Scholar
  31. 31).
    Yokoe T, Iino Y, Sugamata N,et al: Phase II trial of mitoxantrone, doxifluridine and medroxyprogesterone acetate as second-line treatment for anthracycline-resistant metastatic breast cancer.Anticancer Res 15:2303–2306, 1995.PubMedGoogle Scholar
  32. 32).
    Iino Y, Yokoe T, Sugamata N,et al: A combination chemoendocrine therapy of mitoxantrone, doxifluridine, and medroxyprogesterone acetate for anthracycline-resistant advanced breast cancer.Cancer Chemother Pharmacol 41:243–247, 1998.PubMedCrossRefGoogle Scholar
  33. 33).
    Purohit A, Singh A, Ghilchik MW,et al: Inhibition of tumor necrosis factor alpha-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol.Biochem Biophys Res Commun 261:214–217, 1999.PubMedCrossRefGoogle Scholar
  34. 34).
    Sawada N, Ishikawa T, Fukase Y,et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.Clin Cancer Res 4:1013–1019, 1998.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2000

Authors and Affiliations

  • Takao Yokoe
    • 1
  • Yuichi lino
    • 1
  • Yasuo Morishita
    • 2
  1. 1.Emergency and Critical Care MedicineGunma University School of MedicineGunma
  2. 2.Second Department of SurgeryGunma University School of MedicineGunma
  3. 3.Emergency and Critical Care MedicineGunma University School of MedicineMaebashi, GunmaJapan

Personalised recommendations